+65 65881289
contact@bilpublishing.com
Email this article 
Polysaccharide from Fruits of Physalis Alkekengi L. Enhances Antitumor Efficacy by a DNA Vaccine
Article ID: 291
DOI: https://doi.org/10.30564/jams.v1i4.291
Abstract
Physalis. alkekengi fruit has long been used in traditional Chinese medicine for tumor therapy. In the present study, using plasmids that encode ovalbumin (OVA) gene, we investigate the adjuvant activity of a polysaccharide fraction (PPSB) isolated from P.alkekengi fruit. Formulation by simple procedures of mixing of the OVA-encoding pCI-neo-sOVA plasmid with PPSB not only induced specific antibody responses, but also induced antigen-specific cytotoxic T lymphocyte (CTL) responses (Graph abstract). Furthermore, immunization using this vaccine prevented the growth of OVA-expressing B16-OVA tumor cell growth in the immunized mice. Thus, we provide evidence supporting the adjuvant activity of PPSB in DNA vaccine against tumor.
Keywords
Full Text:
PDF
References
[1] A. Stachyra, A. Gora-Sochacka, A. Sirko. DNA vaccines against influenza[J]. Acta biochimica Polonica, 2014(61):515-522.
[2] J.R. Greenland, N.L. Letvin. Chemical adjuvants for plasmid DNA vaccines[J]. Vaccine, 2007(25):3731-3741.
[3] J. Zhou, & Wang, L. Analysis of nutrient composition in the fruit of Physalis alkekengi L[J]. Journal of Nutrition, 1997(19):243-245.
[4] H. Yang, S. Han, D. Zhao, G. Wang. Adjuvant effect of polysaccharide from fruits of Physalis alkekengi L. in DNA vaccine against systemic candidiasis[J]. Carbohydr Polym, 2014(109):77-84.
[5] C.P. Committee. Pharmacopoeia of The People’s Republic of China[M]. China Medical Science Press, Beijing,2010.
[6] H. Tong, Liang, Z., & Wang, G. Structural characterization and hypoglycemicactivity of a polysaccharide isolated from the fruit of Physalis alkekengi L[J]. Carbo-hydrate Polymers, 2008(71):316-323.
[7] G. Xiao, X. Li, A. Kumar, Z. Cui. Transcutaneous DNA immunization following waxing-based hair depilation elicits both humoral and cellular immune responses, European journal of pharmaceutics and biopharmaceutics[J].Official Journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2012(82):212-217.
[8] R. Toll, U. Jacobi, H. Richter, J. Lademann, H. Schaefer, U. Blume-Peytavi, Penetration profile of microspheres in follicular targeting of terminal hair follicles[J]. The Journal of Investigative Dermatology, 2004(123):168-176.
[9] G. Chaouat. The Th1/Th2 paradigm: still important in pregnancy?[C]. Seminars in Immunopathology, 2007(29):95-113.
[10] J. Pol, N. Bloy, F. Obrist, A. Eggermont, J. Galon, W. Herve Fridman, I. Cremer, L. Zitvogel, G. Kroemer, L. Galluzzi. Trial Watch: DNA vaccines for cancer therapy[J]. Oncoimmunology, 2014(3):e28185.
[11] S.G. Reed, S. Bertholet, R.N. Coler, M. Friede. New horizons in adjuvants for vaccine development[J]. Trends in Immunology, 2009(30):23-32.
[12] S.G. Reed, M.T. Orr, C.B. Fox. Key roles of adjuvants in modern vaccines[J]. Nature Medicine, 2013(19):1597-1608.
[13] S.P. Smeekens, M.S. Gresnigt, K.L. Becker, S.C. Cheng, S.A. Netea, L. Jacobs, T. Jansen, F.L. van de Veerdonk, D.L. Williams, L.A. Joosten, C.A. Dinarello, M.G. Netea. An anti-inflammatory property of Candida albicans beta-glucan: Induction of high levels of interleukin-1 receptor antagonist via a Dectin-1/CR3 independent mechanism[J]. Cytokine, 2014(71):215-222.
[14] D. Gordon, P. Kelley, S. Heinzel, P. Cooper, N. Petrovsky. Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: A randomized controlled Phase 1 study[J]. Vaccine, 2014(32):6469-6477.
[15] P.s.C.o.A.o.S.a. Technology, Report to the President on reengineering the influenza vaccine production enterprise to meet the challenges of pandemic influenza[EB/OL].http://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST-Influenza-Vaccinology-Report.pdf, 2010.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.